NLNadina Berrice Lincoln

Nadina Berrice Lincoln

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nadina Berrice Lincoln has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of a UK-wide vignette study with occupational therapists to explore cognitive screening post stroke

    by Jennifer Geraghty, Joanne Ablewhite, Roshan das Nair, Nadina Lincoln, Eirini Kontou, Jack Roffe, Natasha Lannin, Avril Drummond

    Background/Aims There is a paucity of evidence in the UK regarding cognitive screening performed by occupational therapists and whether, and how, cognitive impairments are identified and assessed. The aim of this study was to identify current occupational therapy practice for the assessment of cognitive problems in patients following stroke. Methods Occupational therapists were invited to complete an online vignette study. Participants were asked to: identify any presenting cognitive problems; decide whether to complete cognitive assessments; and list any assessments they would use. Data were analysed using descriptive analysis. Results A total of 53 occupational therapists from across the UK participated. Participants identified key cognitive issues, but some problems, such as apraxia and attention, were overlooked. A large number of potential assessments were suggested, the most common being the Montreal Cognitive Assessment and Oxford Cognitive Screen. Conclusions The variation found in occupational therapists' recognition and assessment of cognitive problems has the potential to impact on management and rehabilitation in stroke services, survivor outcomes, education and research.


  • Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT

    by Nadina B Lincoln, Lucy E Bradshaw, Cris S Constantinescu, Florence Day, Avril Er Drummond, Deborah Fitzsimmons, Shaun Harris, Alan A Montgomery, Roshan das Nair

    Background: People with multiple sclerosis have problems with memory and attention. The effectiveness of cognitive rehabilitation has not been established.Objectives: The objectives were to assess the clinical effectiveness and cost-effectiveness of a cognitive rehabilitation programme for people with multiple sclerosis.Design: This was a multicentre, randomised controlled trial in which participants were randomised in a ratio of 6 : 5 to receive cognitive rehabilitation plus usual care or usual care alone. Participants were assessed at 6 and 12 months after randomisation.Setting: The trial was set in hospital neurology clinics and community services.Participants: Participants were people with multiple sclerosis who had cognitive problems, were aged 18–69 years, could travel to attend group sessions and gave informed consent.Intervention: The intervention was a group cognitive rehabilitation programme delivered weekly by an assistant psychologist to between four and six participants for 10 weeks.Main outcome measures: The primary outcome was the Multiple Sclerosis Impact Scale – Psychological subscale at 12 months. Secondary outcomes included results from the Everyday Memory Questionnaire, the 30-Item General Health Questionnaire, the EuroQol-5 Dimensions, five-level version and a service use questionnaire from participants, and the Everyday Memory Questionnaire – relative version and the Modified Carer Strain Index from a relative or friend of the participant.Results: Of the 449 participants randomised, 245 were allocated to cognitive rehabilitation (intervention group) and 204 were allocated to usual care (control group). Of these, 214 in the intervention group and 173 in the control group were included in the primary analysis. There was no clinically important difference in the Multiple Sclerosis Impact Scale – Psychological subscale score between the two groups at the 12-month follow-up (adjusted difference in means –0.6, 95% confidence interval –1.5 to 0.3;p = 0.20). There were no important differences between the groups in relation to cognitive abilities, fatigue, employment, or carer strain at follow-up. However, there were differences, although small, between the groups in the Multiple Sclerosis Impact Scale – Psychological subscale score at 6 months (adjusted difference in means –0.9, 95% confidence interval –1.7 to –0.1;p = 0.03) and in everyday memory on the Everyday Memory Questionnaire as reported by participants at 6 (adjusted difference in means –5.3, 95% confidence interval –8.7 to –1.9) and 12 months (adjusted difference in means –4.4, 95% confidence interval –7.8 to –0.9) and by relatives at 6 (adjusted difference in means –5.4, 95% confidence interval –9.1 to –1.7) and 12 months (adjusted difference in means –5.5, 95% confidence interval –9.6 to –1.5) in favour of the cognitive rehabilitation group. There were also differences in mood on the 30-Item General Health Questionnaire at 6 (adjusted difference in means –3.4, 95% confidence interval –5.9 to –0.8) and 12 months (adjusted difference in means –3.4, 95% confidence interval –6.2 to –0.6) in favour of the cognitive rehabilitation group. A qualitative analysis indicated perceived benefits of the intervention. There was no evidence of a difference in costs (adjusted difference in means –£574.93, 95% confidence interval –£1878.93 to £729.07) or quality-adjusted life-year gain (adjusted difference in means 0.00, 95% confidence interval –0.02 to 0.02). No safety concerns were raised and no deaths were reported.Limitations: The trial included a sample of participants who had relatively severe cognitive problems in daily life. The trial was not powered to perform subgroup analyses. Participants could not be blinded to treatment allocation.Conclusions: This cognitive rehabilitation programme had no long-term benefits on quality of life for people with multiple sclerosis.Future work: Future research should evaluate the selection of those who may benefit from cognitive rehabilitation.Trial registration: Current Controlled Trials ISRCTN09697576.Funding: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 24, No. 4. See the National Institute for Health Research Journals Library website for further project information.


  • Open Access

    Cognitive rehabilitation for attention and memory in people with multiple sclerosis: a randomized controlled trial (CRAMMS)

    by Nadina B Lincoln, Lucy E Bradshaw, Cris S Constantinescu, Florence Day, Avril Er Drummond, Deborah Fitzsimmons, Shaun Harris, Alan A Montgomery, Roshan das Nair

    To assess the clinical and cost-effectiveness of cognitive rehabilitation for attention and memory problems in people with multiple sclerosis. Multicentre, pragmatic, randomized controlled trial. Community People with multiple sclerosis aged 18–69 years, who reported cognitive problems in daily life and had cognitive problems on standardized assessment. A group cognitive rehabilitation programme delivered in 10 weekly sessions in comparison with usual care. The primary outcome was the Multiple Sclerosis Impact Scale Psychological subscale at 12 months after randomization. Secondary outcomes included measures of everyday memory problems, mood, fatigue, cognitive abilities and employment at 6 and 12 months after randomization. In all, 245 participants were allocated to cognitive rehabilitation and 204 to usual care. Mean Multiple Sclerosis Impact Scale Psychological at 12 months was 22.2 (SD = 6.1) for cognitive rehabilitation and 23.4 (SD = 6.0) for usual care group; adjusted difference −0.6, 95% confidence interval (CI) = −1.5 to 0.3, P = 0.20. No differences were observed in cognitive abilities, fatigue or employment. There were small differences in favour of cognitive rehabilitation for the Multiple Sclerosis Impact Scale Psychological at 6 months and everyday memory and mood at 6 and 12 months. There was no evidence of an effect on costs (−£808; 95% CI = −£2248 to £632) or on quality-adjusted life year gain (0.00; 95% CI = −0.01 to 0.02). This rehabilitation programme had no long-term benefits on the impact of multiple sclerosis on quality of life, but there was some evidence of an effect on everyday memory problems and mood.


  • Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT

    by Shirley A Thomas, Avril Er Drummond, Nadina B Lincoln, Rebecca L Palmer, Roshan das Nair, Nicholas R Latimer, Gemma L Hackney, Laura Mandefield, Stephen J Walters, Rachael D Hatton, et al.

    Background: There is currently insufficient evidence for the clinical effectiveness and cost-effectiveness of psychological therapies for post-stroke depression.Objective: To evaluate the feasibility of undertaking a definitive trial to evaluate the clinical effectiveness and cost-effectiveness of behavioural activation (BA) compared with usual stroke care for treating post-stroke depression.Design: Parallel-group, feasibility, multicentre, randomised controlled trial with nested qualitative research and a health economic evaluation.Setting: Acute and community stroke services in three sites in England.Participants: Community-dwelling adults 3 months to 5 years post stroke who are depressed, as determined by the Patient Health Questionnaire-9 (PHQ-9) or the Visual Analogue Mood Scales ‘Sad’ item. Exclusions: patients who are blind and/or deaf, have dementia, are unable to communicate in English, do not have mental capacity to consent, are receiving treatment for depression at the time of stroke onset or are currently receiving psychological intervention.Randomisation and blinding: Participants were randomised (1 : 1 ratio) to BA or usual stroke care. Randomisation was conducted using a computer-generated list with random permuted blocks of varying sizes, stratified by site. Participants and therapists were aware of the allocation, but outcome assessors were blind.Interventions: The intervention arm received up to 15 sessions of BA over 4 months. BA aims to improve mood by increasing people’s level of enjoyable or valued activities. The control arm received usual care only.Main outcome measures: Primary feasibility outcomes concerned feasibility of recruitment to the main trial, acceptability of research procedures and measures, appropriateness of baseline and outcome measures, retention of participants and potential value of conducting the definitive trial. Secondary feasibility outcomes concerned the delivery of the intervention. The primary clinical outcome 6 months post randomisation was the PHQ-9. Secondary clinical outcomes were Stroke Aphasic Depression Questionnaire – Hospital version, Nottingham Leisure Questionnaire, Nottingham Extended Activities of Daily Living, Carer Strain Index, EuroQol-5 Dimensions, five-level version and health-care resource use questionnaire.Results: Forty-eight participants were recruited in 27 centre-months of recruitment, at a recruitment rate of 1.8 participants per centre per month. The 25 participants randomised to receive BA attended a mean of 8.5 therapy sessions [standard deviation (SD) 4.4 therapy sessions]; 23 participants were allocated to usual care. Outcome assessments were completed by 39 (81%) participants (BA,n = 18; usual care,n = 21). Mean PHQ-9 scores at 6-month follow-up were 10.1 points (SD 6.9 points) and 14.4 points (SD 5.1 points) in the BA and control groups, respectively, a difference of –3.8 (95% confidence interval –6.9 to –0.6) after adjusting for baseline PHQ-9 score and centre, representing a reduction in depression in the BA arm. Therapy was delivered as intended. BA was acceptable to participants, carers and therapists. Value-of-information analysis indicates that the benefits of conducting a definitive trial would be likely to outweigh the costs. It is estimated that a sample size of between 580 and 623 participants would be needed for a definitive trial.Limitations: Target recruitment was not achieved, although we identified methods to improve recruitment.Conclusions: The Behavioural Activation Therapy for Depression after Stroke trial was feasible with regard to the majority of outcomes. The outstanding issue is whether or not a sufficient number of participants could be recruited within a reasonable time frame for a definitive trial. Future work is required to identify whether or not there are sufficient sites that are able to deliver the services required for a definitive trial.Trial registration: Current Controlled Trials ISRCTN12715175.Funding: This project was funded by the NIHR Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 23, No. 47. See the NIHR Journals Library website for further project information.


  • A group memory rehabilitation programme for people with traumatic brain injuries: the ReMemBrIn RCT

    by Roshan das Nair, Lucy E Bradshaw, Hannah Carpenter, Sara Clarke, Florence Day, Avril Drummond, Deborah Fitzsimmons, Shaun Harris, Alan A Montgomery, Gavin Newby, et al.

    Background: People with traumatic brain injuries (TBIs) commonly report memory impairments. These are persistent, debilitating and reduce quality of life, but patients do not routinely receive memory rehabilitation after discharge from hospital.Objective: To assess the clinical effectiveness and cost-effectiveness of a group memory rehabilitation programme for people with TBI.Design: Multicentre, pragmatic, cluster randomised controlled trial. Qualitative and health economic evaluations were also undertaken.Setting: Community settings in nine sites in England.Participants: Participants were aged 18–69 years, had undergone a TBI > 3 months prior to recruitment, reported memory problems, were able to travel to a site to attend group sessions, could communicate in English and gave informed consent.Randomisation and blinding: Clusters of four to six participants were randomised to the memory rehabilitation arm or the usual-care arm on a 1 : 1 ratio. Randomisation was based on a computer-generated pseudo-random code using random permuted blocks of randomly varying size, stratified by study site. Participants and therapists were aware of the treatment allocation whereas outcome assessors were blinded.Interventions: In the memory rehabilitation arm 10 weekly sessions of a manualised memory rehabilitation programme were provided in addition to usual care. Participants were taught restitution strategies to retrain impaired memory functions and compensation strategies to enable them to cope with memory problems. The usual-care arm received usual care only.Main outcome measures: Outcomes were assessed at 6 and 12 months after randomisation. Primary outcome: patient-completed Everyday Memory Questionnaire – patient version (EMQ-p) at 6 months’ follow-up. Secondary outcomes: Rivermead Behavioural Memory Test – third edition (RBMT-3), General Health Questionnaire 30-item version, European Brain Injury Questionnaire, Everyday Memory Questionnaire – relative version and individual goal attainment. Costs (based on a UK NHS and Personal Social Services perspective) were collected using a service use questionnaire, with the EuroQol-5 Dimensions, five-level version, used to derive quality-adjusted life-years (QALYs). A Markov model was developed to explore cost-effectiveness at 5 and 10 years, with a 3.5% discount applied.Results: We randomised 328 participants (memory rehabilitation,n = 171; usual care,n = 157), with 129 in the memory rehabilitation arm and 122 in the usual-care arm included in the primary analysis. We found no clinically important difference on the EMQ-p between the two arms at 6 months’ follow-up (adjusted difference in mean scores –2.1, 95% confidence interval –6.7 to 2.5;p = 0.37). For secondary outcomes, differences favouring the memory rehabilitation arm were observed at 6 months’ follow-up for the RBMT-3 and goal attainment, but remained only for goal attainment at 12 months’ follow-up. There were no differences between arms in mood or quality of life. The qualitative results suggested positive experiences of participating in the trial and of attending the groups. Participants reported that memory rehabilitation was not routinely accessible in usual care. The primary health economics outcome at 12 months found memory rehabilitation to be £26.89 cheaper than usual care but less effective, with an incremental QALY loss of 0.007. Differences in costs and effects were not statistically significant and non-parametric bootstrapping demonstrated considerable uncertainty in these findings. No safety concerns were raised and no deaths were reported.Limitations: As a pragmatic trial, we had broad inclusion criteria and, therefore, there was considerable heterogeneity within the sample. The study was not powered to perform further subgroup analyses. Participants and therapists could not be blinded to treatment allocation.Conclusions: The group memory rehabilitation delivered in this trial is very unlikely to lead to clinical benefits or to be a cost-effective treatment for people with TBI in the community. Future studies should examine the selection of participants who may benefit most from memory rehabilitation.Trial registration: Current Controlled Trials ISRCTN65792154.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 23, No. 16. See the NIHR Journals Library website for further project information.


  • Evaluation of NeuroPage as a memory aid for people with multiple sclerosis: A randomised controlled trial

    by Rachel A Goodwin, Nadina B Lincoln, Roshan das Nair, Andrew Bateman

    Memory problems are reported in 40%–60% of people with multiple sclerosis (MS). These problems affect independence and may limit the ability to benefit from rehabilitation. Our aim was to evaluate the effectiveness of NeuroPage for people with MS living in the community. A multicentre, single-blind, randomised controlled crossover trial was conducted. The intervention comprised the NeuroPage service, which sends reminder messages to mobile phones at pre-arranged times. In the control condition participants received “non-memory texts”, that is, messages not aimed at providing a reminder; for example, supplying news headlines or sport updates. Outcome measures were completed using postal questionnaires after each condition. There were 38 participants aged 28 to 72 (mean 48, SD 11) and 10 (26%) were men. There were no significant differences between NeuroPage and control conditions on the Everyday Memory Questionnaire (p = 0.41, d = 0.02). The number of daily diary items forgotten in the NeuroPage condition was significantly less than in the control (9% vs. 31%, p = 0.01, d = −0.64). Psychological distress was less in the NeuroPage condition than control (p = 0.001, d = −0.84). Further evaluation of the effect on everyday memory is required.


  • Assessing memory rehabilitation outcomes using Adaptation to Memory Difficulties Outcome questionnaire

    by Rachel Harnell, Roshan Dasnair, Nadina B Lincoln

    Background/Aims: There are few measures available to assess the outcome of cognitive rehabilitation. The Adaptation to Memory Difficulties Outcome questionnaire was designed to assess the outcome of memory rehabilitation. The aim of this study was to examine the internal consistency and concurrent validity of the Adaptation to Memory Difficulties Outcome questionnaire, and to evaluate its responsiveness to change for people with traumatic brain injury who received memory rehabilitation. Methods: The Everyday Memory Questionnaire was administered as a baseline assessment in a randomised controlled trial of memory rehabilitation. Participants in the intervention group received ten weekly group memory rehabilitation sessions. The Adaptation to Memory Difficulties Outcome questionnaire was administered at the first and last intervention session. Findings: Of the 171 participants randomised to the intervention group, 118 completed the Everyday Memory Questionnaire and Adaptation to Memory Difficulties Outcome questionnaire. The internal consistency of all subscales was acceptable to good (alpha>0.7), with the exception of the control subscale, which was unacceptable. There were statistically significant but low correlations (rs 0.17 to 0.34, p<0.05) between the Everyday Memory Questionnaire and the three subscales of the Adaptation to Memory Difficulties Outcome questionnaire section A, before treatment. There was a statistically significant improvement (p<0.001) between baseline and follow-up for all subscales on the Adaptation to Memory Difficulties Outcome questionnaire with large effect sizes (0.59-0.94). Conclusions: The Adaptation to Memory Difficulties Outcome questionnaire had good internal consistency on most scales and was responsive to change, but assesses different aspects of memory rehabilitation outcome from the Everyday Memory Questionnaire.

  • The Nottingham Fatigue After Stroke (NotFAST) study: results from follow-up six months after stroke

    by Louise Hawkins, Nadina B. Lincoln, Nikola Sprigg, Nick S. Ward, Amit Mistri, Pippa Tyrrell, Esme Worthington, Avril Drummond

    (2017). The Nottingham Fatigue After Stroke (NotFAST) study: results from follow-up six months after stroke. Topics in Stroke Rehabilitation: Vol. 24, No. 8, pp. 592-596.


  • Cognitive Rehabilitation for Memory Deficits After Stroke

    by Roshan das Nair, Heather Cogger, Esme Worthington, Nadina B. Lincoln, Bernhardt J, Zorowitz R, Becker K, Keller E, Saposnik G, Strbian D, et al.

    Memory problems are common after a stroke, leading to difficulties in everyday life. Memory rehabilitation aims to help retrain lost functions or to teach patients strategies to compensate for them. Although some studies have reported positive outcomes after memory rehabilitation, reviews have provided inconclusive evidence for effectiveness.\ud This is an update of a Cochrane review first published in 2000 and subsequently updated in 200


  • Open Access

    Behavioural Activation Therapy for Depression after Stroke (BEADS): a study protocol for a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression

    by Shirley A. Thomas, Elizabeth Coates, Roshan das Nair, Nadina B. Lincoln, Cindy Cooper, Rebecca Palmer, Stephen J. Walters, Nicholas R. Latimer, Timothy J. England, Laura Mandefield, et al.

    There is currently insufficient evidence for the clinical and cost-effectiveness of psychological therapies for treating post-stroke depression. BEADS is a parallel group feasibility multicentre randomised controlled trial with nested qualitative research and economic evaluation. The aim is to evaluate the feasibility of undertaking a full trial comparing behavioural activation (BA) to usual stroke care for 4 months for patients with post-stroke depression. We aim to recruit 72 patients with post-stroke depression over 12 months at three centres, with patients identified from the National Health Service (NHS) community and acute services and from the voluntary sector. They will be randomly allocated to receive behavioural activation in addition to usual care or usual care alone. Outcomes will be measured at 6 months after randomisation for both participants and their carers, to determine their effectiveness. The primary clinical outcome measure for the full trial will be the Patient Health Questionnaire-9 (PHQ-9). Rates of consent, recruitment and follow-up by centre and randomised group will be reported. The acceptability of the intervention to patients, their carers and therapists will also be assessed using qualitative interviews. The economic evaluation will be undertaken from the National Health Service and personal social service perspective, with a supplementary analysis from the societal perspective. A value of information analysis will be completed to identify the areas in which future research will be most valuable. The feasibility outcomes from this trial will provide the data needed to inform the design of a definitive multicentre randomised controlled trial evaluating the clinical and cost-effectiveness of behavioural activation for treating post-stroke depression. Current controlled trials ISRCTN12715175